Alfacell Corp. said Friday that it will expand its Phase IIclinical trials of Onconase to include treatment of cancerpatients with malignant mesothelioma, a lung cancerassociated with asbestos exposure, and to urothelialcarcinoma, a form of bladder cancer.
The company is already conducting Phase II trials of Onconasein patients with solid tumors. Phase I/II trials are under wayin pancreatic cancer patients. Those trials combine Onconasewith Tamoxifen, a drug used to treat breast cancer.
Onconase is a natural purified protein whose mode of action isunknown.
The Bloomfield, N.J., company's stock is traded over thecounter on the "pink sheets."
(c) 1997 American Health Consultants. All rights reserved.